Showing 2181-2190 of 5957 results for "".
- CooperVision Introduces Online Training to Help ECPs Upgrade Contact Lens Patients to Silicone Hydrogel 1-Day Lenseshttps://modernod.com/news/coopervision-introduces-online-training-to-help-ecps-upgrade-contact-lens-patients-to-silicone-hydrogel-1-day-lenses/2479834/To help eye care professionals grow their silicone hydrogel 1-day contact lens business, CooperVision is unveiling a new, comprehensive online training program that can be completed at any place and time. The web-based training and on-demand webinar focus on teaching practitioners and staff how t
- Ziemer to Implement Low Energy Lenticule Extraction Applications for its Femtosecond Laser Platformhttps://modernod.com/news/ziemer-announces-to-implement-low-energy-lenticule-extraction-applications-to-its-femtosecond-laser-platform/2479888/Ziemer Ophthalmic Systems announced plans to incorporate lenticule extraction capabilities for its flagship LDV Z8 femtosecond laser system.1 “From the very first days of developing the femtosecond l
- Contact Lens Companies Seek Summary Judgment in Lawsuit Over Minimum Pricinghttps://modernod.com/news/contact-lens-companies-seek-summary-judgment-in-lawsuit-over-minimum-pricing/2479910/Three contact lens companies and a distributor, who are defendants in a class-action lawsuit over pricing, filed a motion seeking a summary judgment in the matter in U.S. District Court for the Middle District of Florida here earlier this week, according to a
- ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-announces-publication-on-qr-110-for-lebers-congenital-amaurosis-10/2479967/ProQR Therapeutics announced the publication of a peer-reviewed manuscript describing the preclinical validation for the use of QR-110 in the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal
- Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-fda-acceptance-of-nda-resubmission-for-dextenza/2480009/Ocular Therapeutix announced that it has received acknowledgement from the FDA that the new drug application (NDA) for Dextenza has been received. Dextenza (dexamethasone insert) 0.4 mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery. T
- LensGen Announces Funding And Patent Successhttps://modernod.com/news/lensgen-announces-funding-and-patent-success/2480017/LensGen, a private California company developing the world’s first modular, fluid-optic, curvature changing IOL, is reporting significant progress in its effort to transform how presbyopia is addressed, according to a company news release. The company successfully achieved a key clin
- CHOP Researchers Develop Highly Specific Predictive Screening Tool for Retinopathy in Premature Infantshttps://modernod.com/news/chop-researchers-develop-highly-specific-predictive-screening-tool-for-retinopathy-in-premature-infants/2480024/A multi-hospital collaboration led by researchers at Children’s Hospital of Philadelphia (CHOP) has found a simple method of determining which premature infants should be screened for retinopathy of prematurity (ROP). The recommendations have the potential t
- Ocular Therapeutix Announces NDA Resubmission of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-nda-resubmission-of-dextenza/2480054/Ocular Therapeutix has announced the resubmission of the company’s new drug application (NDA) to the FDA for its lead product candidate Dextenza (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmission is intended to address manufacturing defic
- Takeda Reaches Deal to Buy Shire for $62 Billionhttps://modernod.com/news/takeda-reaches-deal-to-buy-shire-for-around-62-billion/2480166/After several failed attempts, Japanese drugmaker Takeda Pharmaceutical managed to reach an agreement to acquire Shire in a $62 billion deal. The offer is approximately 46 percent cash and 54 percent stock, leaving Shire shareholders owning around half of the combined group. Shire investors will
- J&J Vision Introduces Artificial-Intelligence Powered Virtual Assistant for Contact Lenseshttps://modernod.com/news/jj-vision-introduces-artificial-intelligence-powered-virtual-assistant-for-contact-lenses/2480195/Johnson & Johnson Vision introduced Andy, a virtual assistant chatbot powered by artificial intelligence (AI). Andy is designed to help guide U.S. consumers throughout their Acuvue brand contact lens journey – from those considering contact lenses for the first time to long-term wearers. The